Agios' IDH Inhibitors Show Their Mettle At ASH
Executive Summary
Updates for key products from Agios bring comfort for analysts as it forges ahead with a filing and new studies in AML. Another of its investigational products is also showing first-in-class potential in pyruvate kinase deficiency.
You may also be interested in...
Tibsovo Approval Makes Agios’ Second AML Approval In A Year; Priced At $26k For 30 Days
Tibsovo is the second targeted therapy approved for a mutation-specific subset of relapsed/refractory AML patients. Agios discovered and jointly markets the first, Idhifa, with Celgene.
14 Approvals To Look Out For In Q3
As many as 14 new products are up for US approval in the third quarter, research by Informa Pharma's Biomedtracker shows. Scrip takes a look at the candidates and their chances of reaching the market.
Other ASCO 2018 Highlights – It’s Not All IO
The ASCO annual meeting will stage an upset in the EGFR field in lung cancer, and competition in breast cancer within the CDK4/6 and PI3 kinase inhibitor classes will get tighter. Loxo could once again steal the show with a tissue-agnostic drug, this time targeting RET.